Advicenne
ALDVI.PA operates in the Pharmaceuticals & Medical Research industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.
Business. ALDVI.PA is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. It is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALDVI.PA is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the Pharmaceuticals industry. It is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
The company's capital structure is characterized by a negative operating cash flow of $3.727 billion, indicating a cash outflow from operations, which may signal financial stress or heavy investment in R&D or other long-term initiatives. The liquidity position cannot be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents, which raises concerns about the company's ability to meet short-term obligations.
Profitability metrics are not available in the valuation snapshot, but the negative operating cash flow suggests that the company is not currently generating positive cash from its core operations. This could imply that the company is in a growth or development phase, or it may be facing operational inefficiencies or high costs that are not being offset by revenue.
Segment and geographic exposure details are not disclosed in the available data, making it difficult to assess the company's revenue concentration or diversification across different markets or product lines. Without this information, it is challenging to evaluate the company's exposure to regional economic fluctuations or market-specific risks.
The company's growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. The absence of analyst estimates for revenue growth or decline in the next fiscal year further limits the ability to project future performance.
Risk factors include the inability to assess liquidity risk, which is a significant concern for any business. The low dilution potential suggests that the company is not currently issuing new shares at a high rate, which is a positive sign for existing shareholders. However, the lack of balance-sheet data means that the company's overall financial health and ability to withstand economic downturns cannot be fully evaluated.
Recent events, such as filings or transcripts, are not provided in the available data, which limits the ability to understand the company's recent strategic moves or market reactions. The absence of such information may indicate a lack of transparency or a smaller market presence.
- The company is experiencing a negative operating cash flow, which may indicate financial stress or significant investment in long-term projects.
- Liquidity risk cannot be assessed due to the lack of balance-sheet data and no going-concern language in the source documents.
- Profitability metrics are not available, but the negative operating cash flow suggests operational inefficiencies or high costs.
- Segment and geographic exposure details are not disclosed, making it difficult to assess revenue concentration or diversification.
- Growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance.
- Recent events and strategic moves are not provided, which may indicate a lack of transparency or a smaller market presence.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,21 |
| Revenue | —no estimate | —no estimate | 7,2M |
| Operating income | —no estimate | —no estimate | -2,7M |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- ALDVI.PA Market data — financials · 2026-05-27
- Advicenne SA Market data — analyst estimates · 2026-05-27